Results 1 to 10 of about 3,810 (184)

Pharmacokinetic and pharmacodynamic analyses of terlipressin in patients with hepatorenal syndrome

AAPS Open, 2022
The objective of this population pharmacokinetics (PK) analysis was to characterize the PK of terlipressin and its active metabolite, lysine-vasopressin (L-VP), in patients with hepatorenal syndrome (HRS), following intravenous administration of ...
Xiaofeng Wang, Khurram Jamil
exaly   +2 more sources

Addition of terlipressin to norepinephrine in septic shock and effect of renal perfusion: a pilot study

Renal Failure, 2022
Purpose Terlipressin improves renal function in patients with septic shock. However, the mechanism remains unclear. Here, we aimed to evaluate the effects of terlipressin on renal perfusion in patients with septic shock.Materials and Methods This pilot ...
Jinlong Wang, Mengjuan Shi, Lili Huang, Qing Li, Shanshan Meng, Jingyuan Xu, Ming Xue, Jianfeng Xie, Songqiao Liu, Yingzi Huang   +9 more
doaj   +2 more sources

Mapping the hemodynamic effects of terlipressin in patients with hepatorenal syndrome using advanced magnetic resonance imaging [PDF]

JHEP Reports
Background & aims: Terlipressin improves renal function in ∼40% of patients with hepatorenal syndrome–acute kidney injury (HRS-AKI). Nonetheless, the pathophysiological mechanisms of terlipressin remain unclear.
Karen Vagner Danielsen, Jens Dahlgaard Hove, Puria Nabilou, Thit Mynster Kronborg, Signe Wiese, Hartwig Roman Siebner, Robert Scott, Susan T. Francis, Guruprasad P. Aithal, Søren Møller, Flemming Bendtsen   +10 more
doaj   +2 more sources

The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review [PDF]

BMC Anesthesiology
Background Intraoperative hypotension is a recognized risk factor for delayed graft function (DGF) after kidney transplantation and may compromise both short- and long-term allograft outcomes.
Wen-He Yang, Xin-Lu Chang, Liang Zhang, Lei Wan, Yi Cheng, Yi-Chen Zhu, Fu-Shan Xue   +6 more
doaj   +2 more sources

Effectiveness and safety evaluation of terlipressin in the treatment of intestinal paralysis in end-stage liver disease [PDF]

BMC Gastroenterology
Background and aims Intestinal paralysis is a common complication in end-stage liver disease (ESLD), our aim is to assess the effectiveness and safety of low-dose terlipressin for treating intestinal paralysis in ESLD.
Xia Wan, Hua Xu, Hu Li, Shan Zhong, Yu Lei, Huan Deng, Xiao Fu, Zhi Zhou   +7 more
doaj   +2 more sources

Terlipressin in combination with albumin as a therapy for hepatorenal syndrome in patients aged 65 years or older

Annals of Hepatology, 2023
Introduction and Objectives: Clinical data for older patients with advanced liver disease are limited. This post hoc analysis evaluated the efficacy and safety of terlipressin in patients aged ≥65 years with hepatorenal syndrome using data from 3 Phase ...
Muhammad A. Mujtaba, Ann Kathleen Gamilla-Crudo, Shehzad N. Merwat, Syed A. Hussain, Michael Kueht, Aftab Karim, Muhammad W. Khattak, Peggy J. Rooney, Khurram Jamil   +8 more
doaj   +1 more source

Role of Terlipressin in Cirrhotic Patients with Ascites and without Hepatorenal Syndrome: A Systematic Review of Current Evidence

Canadian Journal of Gastroenterology and Hepatology, 2020
Ascites, a common complication in cirrhosis, is prone to the development of acute kidney injury or hepatorenal syndrome and can be complicated by circulatory dysfunction after paracentesis.
Zhaohui Bai, Yang An, Xiaozhong Guo, Rolf Teschke, Nahum Méndez-Sánchez, Hongyu Li, Xingshun Qi   +6 more
doaj   +1 more source

Improvement of gut-vascular barrier by terlipressin reduces bacterial translocation and remote organ injuries in gut-derived sepsis

Frontiers in Pharmacology, 2022
Gut-vascular barrier (GVB) serves as the last barrier to limit the migration of intestinal toxins into the blood circulation. The efficacy of terlipressin (a vasopressin V1 receptor agonist) in reducing GVB and multiple organ damage in gut-derived sepsis
Zenan Chang, Zenan Chang, Yinan Zhang, Ming Lin, Shihong Wen, Hanjin Lai, Yaqing Zhan, Xiufen Zhu, Zhikun Huang, Xuyu Zhang, Zimeng Liu   +10 more
doaj   +1 more source

Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin II receptor antagonist undergoing coronary artery bypass graft surgery: a randomized controlled study

Ain Shams Journal of Anesthesiology, 2020
Background and objectives Preoperative use of renin angiotensin system antagonists has been considered an independent risk factor for development of vasoplegic syndrome.
Mohamed Saleh, Sherine Kamal Zaki Kodeira, Abdelkhalek Abdelmoneim Aboulseoud   +2 more
doaj   +1 more source

Safety and efficacy of terlipressin in acute-on-chronic liver failure with hepatorenal syndrome-acute kidney injury (HRS-AKI): a prospective cohort study

Scientific Reports, 2022
Terlipressin with albumin, the recommended treatment for hepatorenal syndrome-acute kidney injury (HRS-AKI), is associated with adverse events. Furthermore, the course of AKI in patients with acute-on-chronic liver failure (ACLF) is unknown.
Anand V. Kulkarni, Sowmya Tirumalige Ravikumar, Harshvardhan Tevethia, Madhumita Premkumar, Karan Kumar, Mithun Sharma, Rajesh Gupta, Padaki Nagaraja Rao, Duvvuru Nageshwar Reddy   +8 more
doaj   +1 more source